Case Report HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab 1,2 1,3 4,5 2,6 Elaine Chang, Gustavo Rivero, Niraj R. Patel, Elizabeth Y. Chiao, 8,9 1 7 1,3 Syeling Lai, Kelash Bajaj, John E. Mbue, Sarvari V. Yellapragada Clinical Practice Points We present a case of a veteran with well-controlled unique biology, particularly the near-universal asso- human immunodeﬁciency virus (HIV) infection and ciation with Epstein-Barr virus, regardless of histology, primary refractory classical Hodgkin lymphoma (HL) suggests that immunotherapy may have an important who, after multiple prior lines of therapy, received role in the management of this disease. nivolumab with a complete response. He also devel- Most clinical trials highlighting checkpoint inhibitors oped autoimmune diabetes mellitus after 6 months of have excluded HIV-infected patients. More prospec- nivolumab. tive data is clearly needed to delineate the risks and HIV-associated HL is currently treated under the same beneﬁts of immunotherapy in this population with algorithm as HL in the general population, but its increased autoimmunity at baseline. Clinical Lymphoma, Myeloma & Leukemia, Vol. 18, No. 2, e143-6 ª 2017 Elsevier Inc. All rights reserved. Keywords: Anti-PD-1, Autoimmune diabetes, Human immunodeﬁciency virus, Immune checkpoint inhibitor, Immune-related adverse event
Clinical Lymphoma Myeloma and Leukemia – Elsevier
Published: Feb 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera